These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2025378)

  • 21. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
    Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM
    J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adinazolam mesylate and placebo in depressed outpatients: a 6-week, double-blind comparison.
    Cohn JB; Pyke RE; Wilcox CS
    J Clin Psychiatry; 1988 Apr; 49(4):142-7. PubMed ID: 3281930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
    Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
    J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Placebo response and antidepressant clinical trial outcome.
    Khan A; Detke M; Khan SR; Mallinckrodt C
    J Nerv Ment Dis; 2003 Apr; 191(4):211-8. PubMed ID: 12695731
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adinazolam, a new triazolobenzodiazepine, and imipramine in the treatment of major depressive disorder.
    Amsterdam JD; Kaplan M; Potter L; Bloom L; Rickels K
    Psychopharmacology (Berl); 1986; 88(4):484-8. PubMed ID: 3085137
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A double-blind, placebo-controlled study of paroxetine in depressed outpatients.
    Kiev A
    J Clin Psychiatry; 1992 Feb; 53 Suppl():27-9. PubMed ID: 1531818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amoxapine and imipramine: a double-blind study in depressed patients.
    Sathananthan GL; Matz R; Thompson H; Gershon S
    Curr Ther Res Clin Exp; 1973 Dec; 15(12):919-22. PubMed ID: 4203576
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment of geriatric depression with trazodone, imipramine, and placebo: a double-blind study.
    Gerner R; Estabrook W; Steuer J; Jarvik L
    J Clin Psychiatry; 1980 Jun; 41(6):216-20. PubMed ID: 7380822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A double-blind, placebo-controlled trial of fluvoxamine versus imipramine in outpatients with major depression.
    March JS; Kobak KA; Jefferson JW; Mazza J; Greist JH
    J Clin Psychiatry; 1990 May; 51(5):200-2. PubMed ID: 2110560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients.
    Mendels J; Reimherr F; Marcus RN; Roberts DL; Francis RJ; Anton SF
    J Clin Psychiatry; 1995; 56 Suppl 6():30-6. PubMed ID: 7649971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach.
    Tedeschini E; Fava M; Papakostas GI
    J Clin Psychiatry; 2011 Jan; 72(1):98-113. PubMed ID: 21208576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors that influence the outcome of placebo-controlled antidepressant clinical trials.
    Niklson IA; Reimitz PE; Sennef C
    Psychopharmacol Bull; 1997; 33(1):41-51. PubMed ID: 9133750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paroxetine in major depression: a double-blind trial with imipramine and placebo.
    Cohn JB; Wilcox CS
    J Clin Psychiatry; 1992 Feb; 53 Suppl():52-6. PubMed ID: 1531826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relevance of DMS-III depressive subtype and chronicity of antidepressant efficacy in atypical depression. Differential response to phenelzine, imipramine, and placebo.
    Stewart JW; McGrath PJ; Quitkin FM; Harrison W; Markowitz J; Wager S; Leibowitz MR
    Arch Gen Psychiatry; 1989 Dec; 46(12):1080-7. PubMed ID: 2686575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response of anxiety and agitation symptoms during nefazodone treatment of major depression.
    Fawcett J; Marcus RN; Anton SF; O'Brien K; Schwiderski U
    J Clin Psychiatry; 1995; 56 Suppl 6():37-42. PubMed ID: 7649972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
    Jahn H; Schick M; Kiefer F; Kellner M; Yassouridis A; Wiedemann K
    Arch Gen Psychiatry; 2004 Dec; 61(12):1235-44. PubMed ID: 15583115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy and safety of paroxetine compared with placebo in outpatients with major depression.
    Rickels K; Amsterdam J; Clary C; Fox I; Schweizer E; Weise C
    J Clin Psychiatry; 1992 Feb; 53 Suppl():30-2. PubMed ID: 1531820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
    Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eicosapentaenoic acid versus docosahexaenoic acid in mild-to-moderate depression: a randomized, double-blind, placebo-controlled trial.
    Mozaffari-Khosravi H; Yassini-Ardakani M; Karamati M; Shariati-Bafghi SE
    Eur Neuropsychopharmacol; 2013 Jul; 23(7):636-44. PubMed ID: 22910528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
    Patkar AA; Masand PS; Pae CU; Peindl K; Hooper-Wood C; Mannelli P; Ciccone P
    J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.